These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12818936)

  • 41. Peri-operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel.
    Wheeler DW; Liew TV; Bailey AR
    Anaesthesia; 2007 Feb; 62(2):186-9. PubMed ID: 17223814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin.
    Nicolaides C; Giannakakis T; Skarlos D; Athanassiadis A; Fountzilas G; Damigos D; Pavlidis N
    J Exp Clin Cancer Res; 1998 Mar; 17(1):71-5. PubMed ID: 9646236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the tracing effect of carbon nanoparticle and carbon nanoparticle-epirubicin suspension in axillary lymph node dissection for breast cancer treatment.
    Du J; Zhang Y; Ming J; Liu J; Zhong L; Liang Q; Fan L; Jiang J
    World J Surg Oncol; 2016 Jun; 14(1):164. PubMed ID: 27335011
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
    Ryberg M; Nielsen D; Skovsgaard T; Hansen J; Jensen BV; Dombernowsky P
    J Clin Oncol; 1998 Nov; 16(11):3502-8. PubMed ID: 9817267
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy for breast cancer during pregnancy: is epirubicin safe?
    Mir O; Berveiller P; Rouzier R; Goffinet F; Goldwasser F; Treluyer JM
    Ann Oncol; 2008 Oct; 19(10):1814-5. PubMed ID: 18765465
    [No Abstract]   [Full Text] [Related]  

  • 46. [Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
    Wang P; Zhang S; Zhang XB; Li WJ; Hao XM; Zhang J
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):135-9. PubMed ID: 23714670
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Allergic contact dermatitis due to epirubicin.
    Ventura MT; Dagnello M; Di Corato R; Tursi A
    Contact Dermatitis; 1999 Jun; 40(6):339. PubMed ID: 10385350
    [No Abstract]   [Full Text] [Related]  

  • 48. Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.
    Lee YR; Kang MH; Park HM
    Can Vet J; 2015 Jun; 56(6):571-4. PubMed ID: 26028676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genome-wide association study of epirubicin-induced leukopenia in Japanese patients.
    Srinivasan Y; Sasa M; Honda J; Takahashi A; Uno S; Kamatani N; Kubo M; Nakamura Y; Zembutsu H
    Pharmacogenet Genomics; 2011 Sep; 21(9):552-8. PubMed ID: 21799462
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: the LITE (Liposomal doxorubicin-Investigational chemotherapy-Tissue Doppler imaging Evaluation) randomized pilot study.
    Lotrionte M; Palazzoni G; Abbate A; De Marco E; Mezzaroma E; Di Persio S; Frati G; Loperfido F; Biondi-Zoccai G
    Int J Cardiol; 2013 Aug; 167(3):1055-7. PubMed ID: 23174173
    [No Abstract]   [Full Text] [Related]  

  • 51. Epirubicin-containing high-dose chemotherapy followed by autologous hematopoietic progenitor cell transfusion for patients with chemotherapy-sensitive metastatic breast cancer: results of 5-year follow-up.
    Ito Y; Mukaiyama T; Ogawa M; Mizunuma N; Takahashi S; Aiba K; Horikoshi N
    Cancer Chemother Pharmacol; 1999; 43(1):8-12. PubMed ID: 9923535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
    Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
    Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer.
    De Rosa L; Lalle M; Perillo A; Pierelli L; Salerno MG; Cortesi E; Martelli O; Pandolfi A; Amodeo R; Marzetti L; Mancuso S; Scambia G
    Anticancer Res; 2001; 21(2B):1367-70. PubMed ID: 11396215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epirubicin approved for breast cancer treatment.
    Miller JL
    Am J Health Syst Pharm; 1999 Nov; 56(21):2177. PubMed ID: 10565690
    [No Abstract]   [Full Text] [Related]  

  • 55. Change of formulation decreases venous irritation in breast cancer patients receiving epirubicin.
    Nagata K; Egashira N; Yamada T; Watanabe H; Yamauchi Y; Oishi R
    Support Care Cancer; 2012 May; 20(5):951-5. PubMed ID: 21519948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epirubicin for breast cancer during pregnancy: a case report.
    Eedarapalli P; Biswas N; Coleman M
    J Reprod Med; 2007 Aug; 52(8):730-2. PubMed ID: 17879836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Current status of epirubicin in the treatment of breast neoplasm].
    Jiang ZF; Song SC
    Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):193-5. PubMed ID: 15949413
    [No Abstract]   [Full Text] [Related]  

  • 58. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
    Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility study.
    Fountzilas G; Nicolaides C; Aravantinos G; Skarlos D; Kosmidis P; Papakostas P; Stathopoulos GP; Kontostolis E; Bafaloukos D; Pavlidis N
    Oncology; 1998; 55(6):508-12. PubMed ID: 9778614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epirubicin seems to cause venous sclerosis.
    Lennan E; Middleton JM; Luken J
    BMJ; 2005 Oct; 331(7522):966. PubMed ID: 16239707
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.